1,721,400 shares of the stock were exchanged, compared to its average volume of 1,400,000. The company's beta value stood at 2.78.
ILLEGAL ACTIVITY WARNING: "Cytori Therapeutics Inc (NASDAQ:CYTX) Short Interest Down 35.6% in December" was published by StockNewsTimes and is owned by of StockNewsTimes. The average investment recommendation on a scale of 1 to 5 (1 being a strong buy, 3 a hold, and 5 a sell) is 2.30, which implies that analysts are generally neutral in their outlook for CYTX over the next year. The stock closed maximum at $46.32 over the 52 weeks but is now -0.58% away from that point. The smaller number of ABR is the more favorable. In this case performance of tends to percentage rate of return for a stock for a given time frame. During the same period in the prior year, the company earned ($0.26) earnings per share. equities research analysts predict that Cytori Therapeutics will post -0.62 earnings per share for the current fiscal year.
CYTX is now undervalued by -82.69% relative to the average 1-year price target of $2.08 taken from a group of Wall Street Analysts. They are also projecting the Low EPS estimate of $-0.17 and the High EPS estimate of $-0.03.
Taking a broader look brokerage firms' analysts on the street with an expectant view have Cytori Therapeutics (NASDAQ:CYTX) high price target of $5 and with a conservative view have low price target of $0.5. When we see the company's Volatility, it now has a monthly volatility of 17.36% and weekly volatility of 36.11%.
The co's performance for 6 months was reduced of -70.95%, 1-year performance stands at -78.76% and year to date showing isolated positively performance of 12.70%. The stock's quarterly performance specifies a shift of -33.30% and its performance is stands at -77.49% for last twelve month while moved -67.56% for the past six months. Cytori Therapeutics (NASDAQ:CYTX)'s price sits 3.56% above from its SMA 50 of $0.2973 and -49.61% far from the SMA 200 which is at $0.4712. Zacks Investment Research cut shares of Cytori Therapeutics from a "hold" rating to a "sell" rating in a research report on Thursday, November 9th. The 52-Week High range of the stock is $27.48, while the 52-week low range is $10.36. The 20-day RSI for CYTX is 53.85%, which suggests that the stock is not particularly expensive or cheap, and not predisposed to a reactive price movement based on this measure. Cytori Therapeutics (NASDAQ:CYTX)'s price to earnings ratio stood at 0.
Previously Cytori Therapeutics (NASDAQ:CYTX) reported $-0.14 earnings per share (EPS) for the quarter, beating the consensus estimate of $-0.16 by $0.02. A low P/E can indicate either that a company may now be undervalued or that the company is doing exceptionally well relative to its past trends. The most recent bid on the stock was registered at $0.34. Cytori Therapeutics (NASDAQ:CYTX)'s price to sales ratio for trailing twelve month stands at 0.87, whereas its price to book ratio for the most recent quarters is at 1.48. Short-term as well long term investors always focus on the liquidity of the stocks so for that concern, liquidity measure in recent quarter results of the company was recorded 3.30 as current ratio and on the opponent side the debt to equity ratio was 0.82 and long-term debt to equity ratio also remained 0.76.
- Sells 1401 Shares of Sherwin-Williams Co (SHW)
- Take decisive action against terror group: USA tells Pakistan
- Lobbying for a deal on DACA in Washington
- FY2020 Earnings Estimate for Oceaneering International Issued By Jefferies Group (NYSE:OII)
- Mourinho offer no assurances over Mkhitaryan future
- Trump says U.S. could 'go back in' to Paris climate agreement
- Stryker (SYK) EPS Estimated At $1.95; Isramco (ISRL) SI Decreased By 12.86%
- Dark Souls is coming to Nintendo Switch
- Bullish Two Hundred Day Moving Average Cross - ARI
- McCormick & Company, Incorporated (NYSE:MKC) Position Increased by Neuberger Berman Group LLC